Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-...
Q1 2026
May 14, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 11, 2025